| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA825: Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis |
|
Medicine details |
|
| Medicine name | avacopan (Tavneos®) |
| Formulation | 10 mg hard capsule |
| Reference number | 5035 |
| Indication | In combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) |
| Company | Vifor Fresenius Medical Care Renal Pharma UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 14/04/2022 |
| NICE guidance | TA825: Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Commercial arrangement | PAS |